Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

ENDpoiNTs · Novel Testing Strategies for Endocrine Disruptors in the Context of Developmental NeuroToxicity

H2020Status: CLOSED1 January 201930 June 2024EU funding €6,889,033Call H2020-SC1-BHC-2018-2020

Clear evidence supports associations between endocrine disrupting chemical (EDC) exposure and impaired neurodevelopment. Yet, current hazard assessment of EDCs does not address developmental neurotoxicity. This is due to lack of scientific knowledge on how endocrine disruption is linked to developmental neurotoxicity (DNT). Thus there is an urgent need for novel testing and screening tools to address ED-induced DNT, based on new scientific knowledge. This calls for rapid advances in basic research as well as in the development of screening and testing tools close to the end-users. ENDpoiNTs will address this need by i) integrating advanced expertise in the EDC and DNT fields, two so far rather independent toxicology communities, and ii) continuous interaction with European and international key stakeholders. By combining state-of-the-art in silico and in vitro tools, innovative experimental designs and technologies, and advanced biostatistics on human epidemiological and biomonitoring data, ENDpoiNTs will 1) Generate the necessary scientific insights on the correlative and causal links between endocrine disruption and DNT; 2) Develop predictive in silico tools for chemical screening using machine learning and combination of evidence; 3) Develop and validate in vitro tools for chemical screening and testing that address sex- and species differences; 4) Develop novel molecular endpoints for existing animal-based test guidelines by integrating in vitro, in vivo, and human omics data with behavioural outcomes; 5) Ensure human relevance by linking experimental and epidemiological evidence; 6) Develop an integrated testing approach based on the developed in silico, in vitro, and in vivo assays and molecular markers; 7) Ensure regulatory relevance by developing strategies for implementation of these tools and endpoints into regulatory frameworks. In this way, ENDpoiNTs will meet the scientific, regulatory, and societal needs for improved hazard and risk assessment of EDCs

Consortium · 19 organisations

coordinator

UPPSALA UNIVERSITET

SE · €1,048,434

participant

THE UNIVERSITY OF QUEENSLAND

AU

participant

STICHTING VU

NL · €926,776

participant

INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE

FR · €315,525

participant

IUF - LEIBNIZ-INSTITUT FUR UMWELTMEDIZINISCHE FORSCHUNG GMBH

DE · €1,071,300

participant

UNIVERSIDAD COMPLUTENSE DE MADRID

ES · €199,375

participant

UMEA UNIVERSITET

SE · €198,750

participant

MURDOCH CHILDRENS RESEARCH INSTITUTE PUBLIC COMPANY LBG

AU

participant

UNIVERSITA DEGLI STUDI DI MILANO

IT · €898,518

participant

KAROLINSKA INSTITUTET

SE · €231,745

participant

UNIVERSITY OF MELBOURNE

AU

participant

UNIVERSITAT KONSTANZ

DE · €300,000

participant

BRUNEL UNIVERSITY LONDON

UK · €112,500

participant

UNIVERSITEIT UTRECHT

NL · €632,134

participant

GREEN TOX GMBH

CH · €411,890

thirdParty

MUSEUM NATIONAL D'HISTOIRE NATURELLE

FR

participant

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

FR · €315,438

participant

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

US · €124,973

participant

KARLSTADS UNIVERSITET

SE · €101,677

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.